Immunotoxin in Treating Patients With Leukemia or Lymphoma

Completed · Phase 1

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Immunotoxins can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of LMB-2 immunotoxin in treating patients who have leukemia or lymphoma.

Key facts

Study ID

NCT00002765

Run by

National Cancer Institute (NCI)

Starts

1996-04-01

Last updated by the study team

2015-04-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Laboratory of Molecular Biology — Bethesda, Maryland, United States
• Medicine Branch — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.